The 2024 American Diabetes Association (ADA) Diabetes Standards recommend that adults with T2DM who are at high risk for or already have atherosclerotic cardiovascular disease (ASCVD), heart failure, and/or chronic kidney disease should receive treatment plans incorporating sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and/or GLP-1 RAs. This evidence concerns the gene SLC5A2 and chronic kidney disease.